Xeris Biopharma Holdings Inc. (NASDAQ:XERS) Q4 2023 Earnings Conference Call March 6, 2024 8:30 AM ET

Company Participants

Paul Edick - Chairman, Chief Executive Officer

Steve Pieper - Chief Financial Officer

Allison Wey - Senior Vice President, Investor Relations

Conference Call Participants

Oren Livnat - HC Wainwright

Glen Santangelo - Jefferies

Chase Knickerbocker - Craig Hallum

Roanna Ruiz - Leerink Partners

David Amsellem - Piper Sandler

Operator

Hello everyone and welcome to the Xeris fourth quarter and full year 2023 financial results conference call and webcast. My name is Emily and I’ll be coordinating your call today.

After the presentation, there will be the opportunity for you to ask any questions, which you can do by pressing star followed by the number one on your telephone keypad.

I’ll now turn the call over to Allison Wey, Senior Vice President of Investor Relations. Please go ahead.

Allison Wey

Thank you Emily. Good morning and welcome to Xeris Biopharma’s fourth quarter and full year 2023 financial results and conference call.

This morning we issued two press releases, one on the company’s financial results and the other on refinancing our debt facility with Hayfin Capital. Both can be found on our website.

We’re joined this morning by Paul Edick, Chairman and CEO, and Steve Pieper, our CFO. After our prepared remarks, we will open the line for questions.

Before we begin, I would like to remind you that this call will contain certain forward-looking statements concerning the company’s future expectations, plans, prospects, and financial performance. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those forward-looking statements. For more information on such risks, please refer to our earnings press release and risk factors included in our SEC filings, including our quarterly report on Form 10-Q. Any forward-looking statements on this call represent our views only as of the date of this call and, subject to applicable law, we disclaim any obligation to update such statements.

I’ll now turn the call over to Paul.

Paul Edick

Thanks Allison. Good morning everyone and thank you for joining us today.

Let me start by thanking everyone who contributed in some meaningful way to us delivering an outstanding year for the company, including the patients we serve, the healthcare providers we enable, and the dedicated Xeris team that executes at a very high level every day.

2023 was an exceptional year of performance and growth for Xeris, highlighted by our total revenue which grew an impressive 49% from 2022 to $164 million in 2023, and ending 2023 with over $72 million in cash. This revenue growth along with Xeris’ strong cash position continues to demonstrate the sustainability of the enterprise we’re building.